GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » ROIC %

Rakovina Therapeutics (TSXV:RKV) ROIC % : -89.52% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Rakovina Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2024 was -89.52%.

As of today (2025-04-09), Rakovina Therapeutics's WACC % is 3.79%. Rakovina Therapeutics's ROIC % is -68.70% (calculated using TTM income statement data). Rakovina Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Rakovina Therapeutics ROIC % Historical Data

The historical data trend for Rakovina Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics ROIC % Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
ROIC %
-43.16 -51.93 -51.31

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.86 -56.35 -61.76 -70.09 -89.52

Competitive Comparison of Rakovina Therapeutics's ROIC %

For the Biotechnology subindustry, Rakovina Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rakovina Therapeutics's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's ROIC % falls into.


;
;

Rakovina Therapeutics ROIC % Calculation

Rakovina Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-2.482 * ( 1 - 0% )/( (5.117 + 4.557)/ 2 )
=-2.482/4.837
=-51.31 %

where

Rakovina Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2024 is calculated as:

ROIC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-3.788 * ( 1 - 0% )/( (4.248 + 4.215)/ 2 )
=-3.788/4.2315
=-89.52 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rakovina Therapeutics  (TSXV:RKV) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Rakovina Therapeutics's WACC % is 3.79%. Rakovina Therapeutics's ROIC % is -68.70% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Rakovina Therapeutics ROIC % Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rakovina Therapeutics Business Description

Traded in Other Exchanges
Address
595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.
Executives
Alfredo De Lucrezia Director, Senior Officer
Michael Liggett Director
Jeffrey Bacha Senior Officer
Mads Daugaard Senior Officer
David Hyman Senior Officer
John Michael Langlands Senior Officer

Rakovina Therapeutics Headlines

No Headlines